On March 9, 2023 Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, reported that the European Patent Office ("EPO") has granted patent EP3870574, which covers key compounds in the Company’s broad portfolio of CTPS1 inhibitor assets (Press release, Step Pharma, MAR 9, 2023, View Source [SID1234628383]). The granting of this patent strengthens the Company’s patent portfolio covering its CTPS1 inhibitor assets, which is currently protected by a range of published and unpublished patent families.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine synthesis, Step Pharma has unlocked the ability to selectively inhibit the de novo pyrimidine synthesis pathway, enabling a highly selective treatment of cancer.

EP3870574 has a filing date of October 2019 and could protect this technical space until October 2039, with a potential for further extensions depending on the timing of future regulatory approvals. The patent will be validated in a number of strategically important countries across Europe.